Skip to content

Author

K. Fackeldey

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Closed-Loop Generative Selection: Convergence, Memory, and Noisy Oracles

Closed-loop generative selection has become a workhorse of computational drug discovery: a learned generative model proposes candidate molecules, a fitness oracle scores them, the best are kept, and the model is retrained on this elite set before the next round. Despite its wide use, the method has lacked a rigorous convergence theory, largely because retraining the model each round breaks the Markov property on which classical evolutionary-algorithm analysis relies. We develop a self-contained theory of convergence and expected running time for this class of algorithms. By recovering a Markov structure on an enlarged state space, we show that elitism makes the search absorbing, and we prove almost-sure convergence together with a runtime bound that decomposes the search into the time spent escaping each fitness level. We then analyse the role of the model's memory---how much of the past it is trained on. When learning improves steadily with more data, deeper memory never hurts; when it does not, an exit-time analysis pinpoints the optimal memory depth and shows that excess memory can actually slow convergence. The theory extends to multi-objective search and to noisy oracles: we quantify how many repeated evaluations certify progress under light-tailed noise, and how robust estimators restore guarantees under heavy tails. Recast in terms of oracle evaluations - the true bottleneck in drug design - the analysis yields a concrete, evaluation-minimal strategy. Areproducible study confirms the predictions, including the surprising cost of excess memory. We close with three open problems.

K. Fackeldey, Christof Schütte · 0 citations
Open access Sep 2026

AI-enhanced adaptive virtual screening of large libraries for ligand discovery.

Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessible, scalable and efficient and supports artificial intelligence (AI) and machine learning (ML) method development. AdaptiveFlow provides a screening-ready version of the Enamine REAL Space, to our knowledge the largest library of ready-to-dock, drug-like molecules, comprising 69 billion compounds, also available in SELFIES format. An 18-dimensional grid of molecular properties prioritizes promising chemical subspaces, with optional active learning, reducing computational costs by orders of magnitude. AdaptiveFlow integrates >1,500 docking protocols, including GPU-accelerated and ML-based methods, and achieves near-linear scaling on up to 5.6 million CPUs in the Amazon Web Services cloud. We identified nanomolar inhibitors of two disease-relevant targets, ferroptosis suppressor protein 1 (FSP1) and poly(ADP-ribose) polymerase 1. Co-crystal structures provided mechanistic insights into FSP1 inhibition. AdaptiveFlow enables drug discovery at unprecedented scale and supports the development of AI-driven methods.

Domiziana Cecchini, AkshatKumar Nigam, Ming Tang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.